A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs TAK 935 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 16 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov
    • 04 May 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top